TetraGenetics has discovered the first functional monoclonal antibodies (mAbs) against several high value and historically intractable drug targets. The company’s proprietary platform generates ion channel proteins linked to the pathogenesis of multiple diseases. This major technological achievement has enabled the discovery and development of highly selective therapeutic antibodies to an area of biology for which they’ve been previously unavailable.


Leaders in the discovery and development of monoclonal antibodies targeting ion channels

Learn more →

Drug Targets and Pipeline

We are focused on developing drugs that modulate ion channels implicated in pain, autoimmune diseases and fibrosis. Learn more →



TetraGenetics Pipeline Status Q4 2020